SLC6A2

Sodium-dependent noradrenaline transporter · P23975 · SLC6A2 on Sugi Atlas →

837,554 patent compounds predicted against SLC6A2, 494,243 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Sulfuric Acid (SCHEMBL4224)	0.87	17/20
Oxalic Acid (SCHEMBL9746)	0.87	16/20
Cadaverine Tartrate (SCHEMBL3757)	0.64	16/20
Hydrochloric Acid (SCHEMBL2541)	0.62	16/20
Oxalic Acid (SCHEMBL3729)	0.53	16/20
SCHEMBL2125	0.72	15/20
Hydrochloric Acid (SCHEMBL1501)	0.71	15/20
Hydrochloric Acid (SCHEMBL2082)	0.63	15/20
SCHEMBL2793	0.53	15/20
Oxalic Acid (SCHEMBL3770)	0.69	14/20
SCHEMBL2468	0.65	14/20
SCHEMBL1822	0.63	14/20
Hydrochloric Acid (SCHEMBL2616)	0.61	14/20
SCHEMBL9747	0.61	14/20
Hydrochloric Acid (SCHEMBL2448)	0.61	14/20
Hydrochloric Acid (SCHEMBL2287)	0.59	14/20
Duloxetine (SCHEMBL3803)	1.00	13/20
(R,R)-Tramadol (SCHEMBL7464)	1.00	13/20
1R,2S-Milnacipran (SCHEMBL8099)	1.00	13/20
Duloxetine (SCHEMBL8291)	1.00	13/20

Clinical trials — most relevant to SLC6A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy	PHASE4	COMPLETED
Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)	PHASE4	COMPLETED
Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype	PHASE4	UNKNOWN
Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder	PHASE2/PHASE3	COMPLETED
Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression	PHASE2/PHASE3	COMPLETED
Monoamine Transporters Genotypes: Risk of PTSD and Related Comorbidities	PHASE3	COMPLETED
18F-mFBG Cardiac Uptake With Lewy Body Dementia	PHASE2	RECRUITING
Effects of Atomoxetine on Cognitive Function in Schizophrenia	PHASE2	COMPLETED
Effects of Atomoxetine in Mild Cognitive Impairment	PHASE2	COMPLETED
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence	PHASE2	COMPLETED
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)	PHASE1	COMPLETED
Stimulant Effects on Brain Activity	PHASE1	COMPLETED
Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2	PHASE1	COMPLETED
Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1	PHASE1	COMPLETED
Emotional Effects of Methylphenidate and MDMA in Healthy Subjects	PHASE1	COMPLETED
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation	EARLY_PHASE1	UNKNOWN
Application of 18F-CP6A PET Imaging in Synucleinopathies	EARLY_PHASE1	NOT_YET_RECRUITING
Autonomic Function in Patients With COPD	nan	COMPLETED
Multimodal Neurobiological Approaches to Explore the Gene-Environment Interactions in ADHD	nan	COMPLETED
Atomoxetine PBPK-PD Clinical Study	nan	COMPLETED
Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy	nan	NOT_YET_RECRUITING
Stem Cell Study of Genetics and Drug Addiction	nan	COMPLETED
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients	nan	UNKNOWN
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers	nan	COMPLETED
18F-FDOPA PET in Neuroendocrine Tumours	nan	NO_LONGER_AVAILABLE
Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder	nan	COMPLETED
Pharmacogenetic Studies on Attention Deficit Hyperactivity Disorder	nan	COMPLETED
A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.	nan	UNKNOWN
Optimizing Medication Management for Mothers With Depression	nan	COMPLETED
Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC6A2 binder may also engage these)

Protein	Name	Similarity
P51143	—	1.000	P51143 →
Q9MYX0	—	1.000	Q9MYX0 →
P31652	—	1.000	P31652 →
P31646	—	1.000	P31646 →
P31661	—	1.000	P31661 →
O55192	—	1.000	O55192 →
P28570	—	1.000	P28570 →
Q9GJT6	—	1.000	Q9GJT6 →
SLC6A11	Sodium- and chloride-dependent GABA transporter 3	1.000	landscape →
SLC6A6	Sodium- and chloride-dependent taurine transporter	1.000	landscape →
O88575	—	1.000	O88575 →
O35316	—	1.000	O35316 →
P51905	—	1.000	P51905 →
P31647	—	1.000	P31647 →
Q9XT49	—	1.000	Q9XT49 →
SLC6A13	Sodium- and chloride-dependent GABA transporter 2	1.000	landscape →
P48029	—	1.000	P48029 →
B4JMC1	—	1.000	B4JMC1 →
SLC6A3	Sodium-dependent dopamine transporter	1.000	landscape →
Q9MZ34	—	1.000	Q9MZ34 →
Q9UN76	—	1.000	Q9UN76 →
P31643	—	1.000	P31643 →
P31650	—	1.000	P31650 →
Q9NP91	—	1.000	Q9NP91 →
P48057	—	1.000	P48057 →
Q8VBW1	—	1.000	Q8VBW1 →
B3NV41	—	1.000	B3NV41 →
Q00589	—	1.000	Q00589 →
Q8VDB9	—	1.000	Q8VDB9 →
B3MRS1	—	1.000	B3MRS1 →